Khaled A. Tolba, MD, MBBCh, discusses the use of afatinib in NRG1 fusion–positive lung adenocarcinoma.
Khaled A. Tolba MD, MBBCh
Advertisement
Articles by Khaled A. Tolba MD, MBBCh
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the potential to target NRG1 fusion–positive lung adenocarcinoma with afatinib (Gilotrif).
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Tolba on Targeting NRG1 Fusions in NSCLCPublished: September 10th 2019 | Updated:
Dr. Tolba on Targeting NRG1 Fusions With AfatinibPublished: September 25th 2019 | Updated:
Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung AdenocarcinomaPublished: September 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5